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Abstract.   
 
Aims: recreational drugs are taken for their positive mood effects, yet their regular 
usage damages wellbeing. The psychobiological mechanisms underlying these 
damaging effects will be debated. 
Methods: the empirical literature on recreational cannabinoids and stimulant drugs 
will be briefly reviewed. A theoretical explanation for how they cause similar types of 
damage will be outlined.        
Results. All psychoactive drugs cause moods and psychological states to fluctuate. 
The acute mood gains underlie their recreational usage, while the mood deficits on 
withdrawal explain their addictiveness. Cyclical mood changes are found with every 
CNS stimulant, and also occur with cannabis. These mood state changes provide a 
surface index for more profound psychobiological fluctuations. Homeostatic balance 
is altered, with repetitive disturbances of the HPA axis, and disrupted patterns of 
cortisol-neurohormonal secretion. Hence these drugs cause increased stress, disturbed 
sleep, neurocognitive impairments, altered brain activity, and psychiatric 
vulnerability. Equivalent deficits occur with novel psychoactive stimulants such as 
mephedrone, and artificial ‘spice’ cannabinoids. These psychobiological fluctuations 
underlie drug dependency, and make cessation difficult. Psychobiological stability 
and homeostatic balance are optimally restored by quitting psychoactive drugs.    
Conclusions: recreational stimulants such as cocaine and sedative drugs like cannabis, 
damage human homeostasis and well-being through similar core psychobiological 
mechanisms.  
 
Keywords:  cannabis - amphetamine - MDMA - spice - cocaine - cognition 
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Introduction.  
 
Current campaigns to decriminalize the use of cannabis for recreational purposes 
have portrayed it as a relatively benign substance. Proponents for cannabis suggest 
that it is a relaxant and euphoriant, which makes the user feel better, and everyone 
should be free to use it. For professionals working in the field of drug dependency, 
this description is very limited in its narrow focus, and fails to cover its many 
adverse effects. It is also extremely worrying, since increasing numbers of people 
are attending drug clinics for cannabis dependency. In the USA around 300,000 
new individuals seek professional help for cannabis dependency each year 
(Herrmann et al, 2015). The United Nations Office on Drugs and Crime has 
published international consensus reports on its damaging health effects (UNODC, 
2011, 2016), while the adverse psychiatric sequelae have also been reviewed 
(Volkow et al, 2014: Copeland et al, 2014). Herbal cannabis  contains a number of 
different cannabinoids, including delta 9-THC which is psychoactive, and 
cannabidiol which is non-psychoactive (or minimally psychoative). Cannabidiol 
has been investigated for a range of potentially  benefical medicinal properties 
(UNODC, 2016). It is however important that medicinal cannabidiol is used as a 
monosubsatnace (and not mixed with THC). The focus of this article is on herbal 
cannabis,  which contains delta 9-THC and is being used for its psychoactive 
properties. One of our core aims is to explain how any acute mood gains, are 
ouweighed by its chronically damaging  effects. The limited empirical data on 
artificial ‘spice’ cannabinoids will also be covered, noting that they can be even 
more damaging to human well-being (Zimmermann et al, 2009; Schifano et al, 
2011, 2015; Downey et al, 2014; Gurney et al, 2014).    
 
A second and rather more complex aim, is to compare the psychobiolgical effects 
of cannabis, with those of the recreational stimulants. The comparative effects of 
different CNS stimulant drugs, such as cocaine, nicotine, methamphetaime and 
MDMA, were the topic for an earlier review in this Human Psychopharmacology 
series (Parrott, 2015). The current article will debate the many psychobiological 
similarities between cannabis and the recreational stimulants. This undertaking may 
be perceived as a rather unusual, since sedative and stimulant drugs are 
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traditionally seen as quite different. There are, however, important precedents for 
debating them within the same  theoretical framework. Wise and Bozarth (1987) 
noted that all addictive drugs displayed the ‘common denominator’ of activation of 
dopaminergic fibres, which led to similar patterns of compulsive drug self-
administration. Koob (2009) focused on the role of allostatic load for all forms of 
drug dependency, with the dysregulation of hedonic-pleasure control, and impaired 
homeostasis. Hence all addictive drugs tended to heighten stress, with impairments 
both to the HPA axis, and to those neural regions underlying motivation and reward 
such as the amygdala. The current article takes a similarly broad and eclectic 
approach. It proposes that there are many similarities in the core psychobiological 
processses altered by these different drugs, and that they underlie the various forms 
of damage they cause in humans (Table 1).  
 
 Acute mood effects. 
 
Cannabis is primarily a sedative drug, whereas CNS stimulant drugs are by 
definition activating and alerting. Hence acute cannabis typically leads to feelings 
of relaxation, whereas stimulant drugs increase physiological arousal and feelings 
of alertness. The neurotransmitter changes which underlie these alerting, sedative, 
and other psychopharmacological effects, are outlined in the follow reviews (Green 
et al, 2003; Cruickshank and Dyer, 2009; Hall, 2015; Panenka et al, 2013). Despite 
these fundamental differences in arousal between CNS stimulants and cannabis, 
there are a number of broad similarities in their overall mood effects. In particular 
the moods they engender comprise a mixture of positive or desired mood states, 
along with other less desirable mood state changes. For instance, the acute  effects 
of recreational cannabis may include positive feelings of sociability, happiness, and 
calmness (Green et al, 2003; Titus et al, 2007); yet cannabis can also generate more 
negative feelings of anxiety, agitation, and suspiciousness (Volkow et al, 2014; 
Hall, 2015). Furthermore there are individual differences in these mood reactions, 
and they can influence the decision to continue (or discontinue) further drug usage. 
Le Strat et al (2009) investigated initial responses to cannabis, and found that those 
experimenters who reported 5 or more positive mood reactions were 28 times more 
likely to become regular cannabis users, than those who reported no positive mood 
reactions.  One interesting research question is which factors cause this variability. 
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Adverse reactions typically occur more often after higher doses, although they also 
occur after low doses in some individuals. So do they reflect ‘hard-wired’ 
differences in personality and/or neurochemistry, or are they more related to 
psychological factors such as expectancy?   
 
CNS stimulant drugs such as amphetamine and cocaine can also intensify a wide 
range of mood states, including some which are positive and desirable, and others 
which are more negative and undesirable. The positive effects of CNS activation 
can include feelings of sociability and happiness, while the more negative moods 
may include feelings of anxiety and tension (Cruickshank and Dyer,  2004; Parrott 
et al, 2004; Carvalho et al, 2013; Panenka et al, 2013). When higher doses are 
taken, the stimulatory effects can be far stronger, with recreational users reporting a 
physical rush or hit, along with feelings of elation or euphoria. Yet these higher 
doses can also lead to intensely negative moods, with pronounced feelings of 
tension, suspiciousness, or clinical paranoia (Carvalho et al, 2013; Panenka et al, 
2013). These positive and negative mood effects can occur together, leading to 
changeable and unpredictable patterns of behaviour. Even the methamphetamine 
derivative MDMA, or ‘ecstasy’, traditionally seen as the most euphoriant of all the 
recreational stimulants, can paradoxically lead to feelings of anger and aggression 
(Reid et al, 2007). Indeed the mixture of positive and negative moods with MDMA, 
has been empirically shown to be similar to the mixed mood profiles generated by 
recreational cocaine (Parrott et al, 2011a), methamphetamine (Parrott et al, 2011b; 
Kirkpatrick et al, 2012), and mephedrone (Jones et al, 2016).  
 
                                                    - Table 1 near here - 
 
Drug withdrawal and repetitive mood vacillation 
 
One of the core problems found with every psychoactive drug, is that the on-drug 
period is followed by a period of neurochemical rebound, when the opposite moods 
develop. All psychoactive drugs can cause these repetitive mood vacillations 
(Parrott, 2008). They may be illustrated by the legal stimulant nicotine, or by the 
illegal stimulant cocaine, since both drugs display rapid profiles of action. For a 
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detailed review of the many pharmacokinetic and pharmacodynamic similarities of 
nicotine and cocaine, in pre-clinical animal research, see Mello (2010). 
Physiologically nicotine is a powerful CNS stimulant, with the first cigarette of the 
day increasing resting heart rate by around 16 bpm, while 4mg nicotine gum can 
increase it by around 6 bpm (Parrott and Winder, 1989). Cigarette smokers report 
feeling more alert after their first cigarette of the day, but this activation is rapidly 
lost, with smokers soon needing another cigarette to maintain alertness. This 
craving for nicotine commences around 20-60 minutes after the last cigarette in 
regular smokers, illustrating how the essence of nicotine dependency is this 
repetitive vacillation in psychobiological states (see Figure 1 in Parrott, 1994). 
Similar patterns of mood fluctuation are also found with cocaine users. Nasal 
insufflation leads to a rapid hit, but this is soon followed by low moods, and the 
desire for another ‘rush’ or ‘hit’. Hence cocaine, just like nicotine, displays a very 
high addiction potential (Cadet et al, 2007; Parrott, 2008, 2015; Mello, 2010; 
Carvalho et al, 2013).   
 
Similar patterns of mood fluctuations are found with every other CNS stimulant.  
Cathinone has slightly weaker CNS stimulant properties than cocaine or 
amphetamine, and is self-administered by chewing Khat leaves. The drug-habit is 
common in countries around the Horn of Africa, and associated immigrant 
communities in Western cities (Parrott, 2007). The mood effects of cathinone have 
been summarised by Aden et al (2006). Khat chewers report mood gains when 
chewing, but these are soon followed by negative moods when not-chewing. The 
same pattern of positive moods on drug, followed by negative moods post-drug, is 
also evident with recreational MDMA or Ecstasy. This methamphetamine derivative 
displays a far longer time profile, so that the acute mood gains take 1 to 4 hours to 
develop and peak, and the post-MDMA recovery period may last for several days. 
Hence recreational Ecstasy/MDMA users report moods such as happiness or euphoria 
for a few hours (Parrott and Lasky, 1998), but they are followed by feelings of 
sadness and unsociability two days later. Curran et al (2004) also found very positive 
moods on-MDMA, but again they were followed by significant levels of aggression 
and depression in the days afterwards. This long pharmacodynamic profile helps to 
explain why Ecstasy/MDMA is typically used intermittently (Parrott, 2005).  
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A similar pattern of repetitive mood vacillation also occurs with cannabis. Vandrey et 
al (2005) compared the profiles of cannabis and tobacco withdrawal symptoms, and 
concluded that the ‘magnitude and time course of withdrawal effects are similar 
across the two syndromes’. The unpleasant mood effects of cannabis withdrawal 
included irritability, anxiety, anger and depression; these negative feelings were 
commonly reported, although to a different extent across individuals (Budney et al, 
2001; Vandrey et al, 2005; Allsop et al, 2014). These adverse feelings are commonly 
reported, with Vandrey et al (2005) finding that 2/3rds of their sample experienced 4 
or more cannabis withdrawal symptoms. Other psychophysiolgial and behavioural 
effects of cannabis withdrawal can include psychmotor agitation, reduced appetite, 
and impaired sleep architecture. The breadth of these psychobiological symptoms can 
make cessation very difficult (Allsop et al, 2014). The key problem is that mood states 
on drug are followed by negative moods off-drug, so causing repetitive mood 
vacillations, and heightening the propensity for drug dependency.  The above studies 
have typically employed standardised questionnaires, such as the Marijuana Craving 
Questionnaire (Heishman et al, 2001), and the Cannabis Withdrawal Discomfort Scale 
(Budney et al, 1999), to measure the severity of withdrawal symptoms.  
 
 
Dependency and addiction potential. 
 
It is widely recognised that all the recreational stimulants are addictive, and for an 
overview of the addictive properties of amphetamine, methamphetamine and cocaine, 
the following reviews are recommended (Cruickshank and Dyer, 2004; Carvalho et al, 
2013; Panenka et al, 2013; Glasner-Edwards and Mooney, 2014). These reviews note 
that two of the most addictive stimulant drugs are ‘ice’ methamphetamine, and ‘crack’ 
cocaine, due to their strength and rapidity of action. Cannabis also shows strong 
addiction potential, with higher strength products such as ‘skunk’ being more 
addictive that normal herbal supplies (Copeland et al, 2014). The more recent 
artificial ‘spice’ cannabinoids, which an be total rather than partial agonists for the 
cannabinoid receptor, are even stronger in their addiction potential (Schifano et al, 
2011, 2015; Steeley et al, 2012; Papanti et al, 2013; Downey et al, 2014). Indeed it 
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has been suggested that they can be just as addictive as the strongest CNS stimulants 
(Zimmermann et al, 2009).  
 
In the USA, it has been estimated that around 300,000 individuals seek professional 
help for cannabis dependency each year (Herrmann et al, 2015).  The proportion of 
cannabis users with clinical dependency has been estimated to be around 10% of 
those who have ever tried the drug (Wagner and Anthony, 2002). More recent reports 
suggest even higher rates of clinical problems, probably due to the more potent strains 
of modern cannabis (Copeland et al, 2014). Furthermore, a far higher proportion of 
cannabis users display sub-clinical levels of dependency. In one large survey of 
British users, 65% of recreational users reported some degree of cannabis 
dependence, although only 3% of this sample had sought clinical treatment (Terry et 
al, 2007).   Regular cannabis users experience adverse moods during withdrawal, and 
the extent of these negative feelings predicts their ‘difficulty in quitting’ (Budney et 
al, 2004). Dependency is greater in frequent users, with around 50% of daily cannabis 
users showing clinical levels of dependency (Coffey et al, 2002). Young initiates are 
also more vulnerable, with commencement before age 17 years, demonstrating an 
eighteen fold increase in subsequent cannabis dependence (Silins et al, 2014). 
Dependent cannabis users suffer more from memory impairments, mental health 
problems, respiratory diseases, financial problems, conflicts with family/friends, and 
occupational or employment problems (Coffey et al, 2003).  
 
The Hypothalamic-Pituitary-Adrenal Axis and homeostasis.  
 
In physiological terms, good health and psychological stability are dependent on 
homeostasis. When homeostasis is disrupted, the organism displays psychological 
imbalance and increased levels of stress (Seyle, 1955). The Hypothalamic-Pituitary-
Adrenal (HPA) axis underlies the maintenance of psychophysiological stability, with 
cortisol being the key neurohormone (Lovallo, 1997). Hence normal healthy 
individuals show a regular circadian rhythm of cortisol secretion, and when the HPA 
axis is disrupted, the organism typically shows signs of stress (Selye, 1955; Parrott, 
2009). CNS stimulant drugs such as cocaine which activate the HPA axis, cause an 
increase in cortisol release, which leads to acute and/or chronic stress (Mello, 2010). 
Cortisol release is similarly heightened by MDMA. In the laboratory, Harris et al 
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(2002) found an acute cortisol increase of 150% after a moderate dose of MDMA. 
While in recreational Ecstasy/MDMA users, Parrott et al (2008) found an acute 
cortisol increase of 800%. Wetherell and Montgomery (2013) found that the Cortisol 
Awakening Response was altered in recreational Ecstasy/MDMA users. Cortisol can 
also be measured in 3-month hair samples, with regular Ecstasy/MDMA users 
displaying a 400% increase in this stress hormone (Parrott et al, 2014). Cannabis can 
also adversely affect the HPA axis. Raganathan et al (2009) showed that acute THC 
administration led to a significant increase in cortisol secretion. In large prospective 
study of Dutch adolescents, Van Leeuwen et al (2011) found that regular users of 
cannabis demonstrated lower hormonal reactivity to a standard laboratory test of 
social stress. King et al (2011) found that chronic cannabis users had significantly 
higher salivary cortisol levels than controls, and noted the implications for changes in 
psychomotor performance and brain activity.  
 
Psychiatric aspects. 
 
The world’s oldest pharmacopeia, attributed to Emperor Shen Nung in China, noted 
that although cannabis had some useful medicinal properties: ‘If taken in excess it 
will produce visions of devils’ (Nung, 1998). Modern research has confirmed that 
cannabis can generate cognitive distortions and a range of psychiatric problems 
(Volkow et al., 2014). Acute cannabis can adversely affect cognitive integrity, by 
inducing bizarre thoughts and feelings of depersonalisation (Ashton, 2001). In a 
placebo-controlled laboratory study, D’Souza and colleagues (2004) administered 
THC to recreational cannabis users without any prior psychiatric history. Acute THC 
led to significant increases in schizophrenia-like symptoms, as assessed using the 
Positive and Negative Symptom Scale (PANSS). The emergent thoughts and bizarre 
cognitions included the following subjective experiences following acute cannabis: ‘I 
thought I could see into the future …I thought I was god’, another volunteer stated: ‘I 
could hear someone typing on the computer…and I thought you were trying to 
program me’; while a third person noted: ‘I thought you could read my mind, that is 
why I did not answer’; many other examples were also given (D'Souza et al, 2004).  
The extent of PANSS positive symptoms induced by tetra-hydrocannabinol has been 
shown to correlate with specific changes in brain activity (Nottage et al, 2015).  
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The psychotic-like effects of acute cannabis wear off as the drug is metabolised and 
excreted, but its regular use can lead to various forms of drug-induced psychosis, and 
other psychiatric problems (Paparelli et al, 2011). The Swedish Conscript study was 
the first prospective investigation to demonstrate an association between cannabis and 
schizophrenia (Andréasson et al, 1987). It has been followed by several further 
prospective studies, and they have also found that recreational cannabis leads to an 
increased risk of psychotic breakdown in later years. In a comprehensive review, Le 
Bec et al (2009) concluded that every prospective study showed a link between 
cannabis use, and the later emergence of psychosis or psychotic symptoms. One 
important modulating factor is the premorbid personality, since some individuals are 
more susceptible to psychiatric breakdown. Henquet et al (2005) prospectively 
followed 2437 young cannabis users with or without a predisposition for psychosis, 
and found an increased risk in both groups, although the effect was more pronounced 
in the predisposed group (Henquet et al, 2005). As with many studies, a highly 
significant dosage effect was present. Cannabis users who used the substance ‘less 
than monthly’ showed no increase in psychotic symptoms (OR= 0.99), those who 
took it ‘1-2 times/week’ showed a significantly increased risk (OR=1.95), and this 
was further increased in those who used cannabis ‘almost daily’ (OR=2.23).  
Cannabis use was also associated with other chronic mental health problems, 
including depression, anxiety, and mania (Richardson, 2010; Bovasso, 2014; Patton et 
al., 2002; Van Laar et al, 2007). Again dosage effects are typically noted, with heavier 
users showing the greater risk. Lubman et al (2015) noted that the ‘endocannabinoid 
system plays an important part in brain development’, and suggested that this may 
explain why heavy cannabis use during adolescence was associated with ‘more severe 
and persistent negative outcomes’, including cognitive impairment and mental illness. 
Levine et al (2017) similarly noted the strong association between heavy cannabis use 
during adolescence, and adverse psychiatric/cognitive outcomes, but noted that it was 
still unclear whether ‘cannabis alone’ was the causal factor. They further noted that 
the animal literature showed that ‘adolescent-onset exposure to cannabinoids can 
catalyze molecular processes that lead to persistent functional deficits in adulthood’, 
and recommended future longitudinal studies with carefully integrated batteries of 
assessment measures.  
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The recreational use of CNS stimulants is also associated with greater psychiatric 
distress. Even comparatively weak CNS stimulants such as cathinone, can lead to 
psychiatric problems. Feyissa and Kelly (2008) undertook a functional review of Khat 
chewing, and concluded that cathinone could induce a range of ‘mood disturbances, 
particularly depression’ in otherwise normal subjects, while some regular users 
developed a form of hypomania. The authors further noted that many of the problems 
of cathinone users were similar to those occurring in regular amphetamine users. 
Indeed the chronic use of recreational amphetamine, cocaine, and methamphetamine, 
can lead to a wide range of adverse psychobiological and/or psychiatric consequences 
(Cadet et al, 2007; Cruickshank and Dyer, 2009; Panenka et al, 2013). The adverse 
psychophysiolgical effects may include tremors, dyskinesias, repetitive stereotypical 
movements, while the adverse psychiatric effects can include anxious irritability, 
anger or physical aggression, feelings of paranoia, and full psychosis (Williamson et 
al, 1997; Fasano et al, 2008; Cruickshank and Dyer, 2009; Panenka et al, 2013; 
Vearrier et al, 2012; Glaser-Edwards and Mooney, 2014). MDMA is a 
methamphetamine derivative, and despite being called ‘Ecstasy’, is also associated 
with a range of adverse psychiatric consequences (Schifano et al, 1998; MacInnes et 
al, 2001; Parrott et al, 2001, 2014a,b; Scholey et al, 2011). Brière et al (2012) 
undertook a prospective study of disadvantaged Canadian schoolchildren, and found 
that youngsters who commenced taking recreational MDMA reported significantly 
higher depression one year later [Note: a similar pattern of increasing depression was 
also found with novice methamphetamine users]. While in another prospective study, 
Turner et al (2014) found that females who quit taking Ecstasy/MDMA, reported 
significantly lower levels of depression over a year later.  In contrast, in a large cross-
sectional study, Taurah et al (2013) found that former users continued to display high 
levels of depression, along with other psychobiological deficits such as impulsiveness, 
poor memory, and disturbed sleep.   
 
Neurocognitive effects. 
 
Many cognitive skills are impaired by acute cannabis, including memory, learning 
new information, sustained attention, higher cognitive abilities such as decision 
making, and more basic abilities such as psychomotor integrity. The regular use of 
cannabis can also lead to a range of cognitive deficits in abstinent users, with the 
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extent of these deficits related to factors, such as frequency and duration of 
recreational usage (Pope et al, 2001; Bolla et al, 2002; Grant et al,  2003; Yücel et al, 
2008). The adolescent brain may also be more susceptible to the adverse effects of 
cannabis (Jager et al, 2010). In long term users who ocmm durin adolescence,  there 
may even be a slow decline in intelligence test scores over time (Meier et al, 2012). 
Neuroimaging studies show that two brain regions particularly affected by cannabis 
are the hippocampus and amygdala, since although cannabinoid receptors are found 
across the whole brain, these regions display high levels of cannabinoid receptor 
density. Dose-related reductions in hippocampal and amygdala volumes have also 
been reported (Yucel et al, 2008). In a review of the adverse effects of cannabis on 
brain structure and activity, Mandelbaum and de la Monte (2016) noted that: 
‘Neuroimaging studies demonstrated that the major targets of cannabis-mediated 
neurodegeneration include white matter in the frontal lobes, fornix, fimbria of the 
hippocampus, frontal-limbic connections, corpus callosum, and commissural fibers. In 
addition, cannabis targets the cerebellar structure and function such that cerebellar 
white matter atrophy can be significant and associated with neurobehavioral deficits 
and psychotic symptoms’. 
 
The recreational use of cocaine, methamphetamine and MDMA, are also associated 
with neurocognitive impairments. Cruickshank and Dyer (2009) noted that 
methamphetamine use was associated with impairments in executive functioning, 
learning of new information, various aspects of memory, and impairments in motor 
skills. The similarity of this list to that described for cannabis users in the previous 
paragraph, may be noted. Many other reviews have generated similar lists of 
neurocognitive impairments, following the use of other CNS stimulant drugs.  
Cocaine users display a wide range of neuropsychological and neurocognitive deficits 
(Soar et al, 2012), with deficits in attention, memory, and executive functioning 
(Vonmoos et al, 2013). Drug-free Ecstasy/MDMA users demonstrate deficits in 
retrospective memory with a meta-analysis showing moderate-to-large effect sizes 
(Laws and Kokkalis, 2007). Other neurocognitive deficits are found with prospective 
memory, executive planning, and problem solving, while complex visual processing 
can also be affected (Fisk et al, 2005; Fox et al, 2002; Mejias et al, 2005; 
Montgomery et al, 2010). 
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Summary and overview. 
 
There are several ways for CNS stimulant drugs to damage the 
neuropsychobiological integrity of the organism. In overall terms, they disrupt 
psychological equilibrium, by acutely stimulating multiple mood states, then 
impairing them during the post-drug recovery period. This vacillation in mood 
states may be seen as an index for more profound psychological changes. So that 
feelings of alertness, confidence, motivation, and sociability, can all show similar 
patterns of repetitive vacillation. Psychobiological vacillation also raises questions 
over their efficacy and safety, when stimulant drugs such as MDMA are being used 
for medicinal or therapeutic purposes (Parrott, 2014). It also explains why every 
CNS stimulant displays a strong addiction potential. The regular user suffers from 
many negative states when off-drug, and feels correspondingly better when on-
drug; this underlies their desire to take the drug repeatedly (Parrott, 1994, 2008). 
All stimulant drugs adversely affect the HPA axis, causing hormonal dysregulation, 
and increasing the susceptibility for psychiatric distress (Table 1). In an earlier 
review (Parrott, 2015) it was noted that the healthy human organism displays a 
natural balance between sympathetic and parasympathetic nervous system activity. 
When humans used recreational stimulant drugs, they disturbed this natural 
balance, and this led to numerous adverse consequences (Parrott, 2015).  
 
Cannabis induces a similar pattern of disrupted homeostasis, despite being 
primarily a sedative. It causes moods to fluctuate, and as with the recreational  
stimulants, this provides the core rationale for its addiction potential (Table 1). The 
regular user may feel ‘better’ on-drug, but afterwards they develop feelings of 
anxiety, anger, or other negative mood states when off-drug. Again this repetitive 
mood fluctuation helps to explain cannabis’s strong addiction potential. Cannabis 
also affects the HPA axis, and by impairing homeostasis, it can disrupt 
psychological integrity and impair sleep (Table 1). The cognitive skills which are 
impaired by cannabis, are also broadly similar to those damaged by recreational 
stimulants such as cocaine or amphetamine. Cannabis can also leads to a wide 
range of psychiatric problems, with spice cannabinoids showing an even greater 
propensity for psychobiological/psychiatric abreactions (Fergusson et al, 2003; 
Zimmermann et al, 2009; Nottage et al, 2015). In summary, despite their very 
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different effects on arousal and feelings of alertness, cannabis and the recreational 
stimulants display a surprisingly similar profile of acute and chronic 
psychobiological effects.  
 
Finally, it is important to educate society about the adverse effects of all these 
psychoactive drugs. Proponents for drug use typically focus on acute drug effects, 
and with this narrow focus, any psychoactive drug could be misperceived as 
beneficial (Parrott, 2008). It is only by covering all aspects of their acute and 
chronic usage that a total picture of their damaging effects emerges. Governments 
need to fund basic education campaigns, describing their adverse health and 
psychobiological consequences. Public health campaigns have been effective at 
educating the public about the adverse effects of tobacco smoking, and have led to 
massive reductions in tobacco usage, while similar or are needed for excessive 
drinking (Parrott et al, 2016). Similar education campaigns are urgently needed for 
both herbal cannabis, and the artificial spice cannabinoids.   
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Table 1. Core psychobiological processes underlying the effects of recreational 
cannabis and CNS stimulant drugs.  
 
 
 Summary of main effects    
Positive/desired 
acute mood effects  
Range of positive mood changes found 
with both classes of drug. Positive moods 
tend to be activating/alerting with CNS 
stimulants, and sedative/relaxant with 
cannabis (. 
Cruickshank and Dyer, 200? 
Le Strat et al, 2009 
Hall, 2015 
 
Negative/unwanted 
acute mood effects 
Range of negative mood changes reported 
with both types of drug. Feeling of stress, 
tension, and loss of control.      
Carvalho et al, 2013 
Volkov et al, 2014 
 
Post drug 
withdrawal 
Negative moods such as irritability and 
depression tend to predominate, with 
similar patterns of drug withdrawal 
following CNS stimulants such as nicotine, 
and sedatives such as cannabis. 
Parrott and Lasky, 1998 
Parrott 1999  
Vandree et al, 2005 
 
 
Repetitive mood 
fluctuations, as 
indices of broader 
changes 
psychological state 
All psychoactive drugs by definition cause 
moods to fluctuate. These mood state 
changes provide a surface index for wider 
and more fundamental fluctuations in 
psychological status. They also provide the 
psychobiological basis for drug addiction. 
Aden et al, 2006 
 
 
Addiction potential This reflects two core factors: strength, and 
rapidity of action. Addiction potential is 
greater in stronger drugs. Hence spice 
cannabinoids are more addictive than plant-
derived street cannabis. Addictiveness 
greater in drugs with a rapid onset and 
withdrawal, such as ‘crack’ cocaine. 
Budney et al, 1999 
Copeland et al, 2014 
Herrmann et al, 2014 
 
Impaired 
homeostasis 
Changes to the Hypothalamic Pituitary 
Adrenal (HPA) axis, with altered patterns 
of cortisol release, and many other 
neurohormonal Homeostasis adversely 
affected, with altered patterns of sleep and 
waking, often accompanied by increased 
stress.   
Van Leeuwen et al, 2011 
Parrott et al, 2014a,b 
 
Psychiatric deficits  
 
Recreational stimulants associated with 
many forms of psychiatric distress. Acute 
cannabis can elicit strange thoughts and 
cognitions. Chronic cannabis use may lead 
to psychosis and other psychiatric 
disorders.  
Volkov et al, 2014 
Downey et al, 2014 
Schifano et al, 2011 
Brier et al, 2013 
 
Neurocognitive 
deficits and 
neuroimaging 
measures brain 
activity 
Neuroimaging and neurocognitive studies 
reveal a range of deficits. Deficits in 
working memory, attention, declarative 
memory, and higher cognitive skills, found 
in regular users of cannabis and CNS 
stimulants. Neuroimaging studies reveal 
chronic changes in brain activity. 
Yucel et al, 2008 
Kish et al, 2010 
Taurah et al, 2013 
Mandelbarum et al, 2016 
 
 
 
